Tina Bhutani, MD, discusses a new article published in the October 2024 issue of JCAD that describes patient-reported symptoms and treatment satisfaction in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab 100mg over 64 weeks.
Reference:
-
- Vasquez JG, Heim JM, Bhutani T, et al. Improvement in Patient-reported Symptoms and Satisfaction with Tildrakizumab in a Real-world Study in Patients with Moderate-to-severe Plaque Psoriasis. J Clin Aesthet Dermatol. 2024;17(10):63–67.